A novel NMDA receptor glycine-site partial agonist, GLYX-13, has therapeutic potential for the treatment of autism
Investigates the role of NMDA receptor modulation in social play vocalizations in rats, exploring GLYX-13 as a potential treatment for autism spectrum disorder.
